Health technology company NeuroMetrix has just released Quell 2.0, a major update to its wearable therapeutic pain management device that provides more power in an even smaller package. Quell is a 100 percent drug-free system that uses transcutaneous electrical nerve stimulation (TENS) to block chronic pain; users wear the device on the leg, regardless of the site of the pain, and neural pulses are sent to the brain that trigger a natural pain relief response in the central nervous system. NeuroMetrix has also announced a new “Intensive Therapy” option for the 2.0 version of the device that provides more intensive nerve stimulation in a shorter 15-minute session, allowing users to opt for a faster pain relief regimen than the standard Quell therapy — a first among wearable TENS devices.
The company is also introducing an update to the Quell app to add coaching features to help users get the best results from the device. Worn as part of a breathable soft fabric band, Quell 2.0 itself is a credit-card sized device so that it can be worn discreetly and comfortably under clothing, and is 50 percent smaller and 20 percent more powerful than its predecessor. Quell 2.0 is rated for a typical battery life of up to 25 hours, and is the only wearable pain device that’s been approved by the FDA for both day and nighttime use and for multiple types and sources of chronic pain.
New machine learning algorithms have also been developed for the new version to add an unprecedented level of personalization to Quell’s chronic pain treatments through the collection and analysis of millions of data points, taking into account such factors as demographics, health conditions, pain levels and characteristics, device utilization and objective measures of sleep, activity and gait from over 70,000 chronic pain sufferers via the Quell Healthcloud. Quell can also adjust therapy based on manual intensity changes, body position, sleep movements, and even changing local weather conditions. Quell 2.0 is available now for $299, with the AI powered capabilities, Intensive Therapy option, and app-based Therapy Coach expected to be coming later this year.
